Learning Programs

This webinar will present an overview of Alzheimer’s disease (AD). It provides key facts and figures about dementia and AD in Canada including the socioeconomic burden associated with dementia due to AD and the populations and individuals at high risk of dementia and/or facing barriers to equitable care. The presentation then goes on to describe the various mechanisms that contribute to neurodegeneration and AD, the various types of AD, as well as the risk factors for AD, both non-modifiable and potentially modifiable, and the possible protective factors. The diagnostic pathway and stages of AD are also examined, followed by an exploration of the current treatment options and diagnostic guidelines.

This webinar will describe the various steps involved in the clinical assessment of a patient with a cognitive complaint or informant concern. It highlights the different assessment tools currently used to detect cognitive impairment, functional impairment, and neuropsychiatric symptoms, and how to administer the commonly used tests. It includes an overview of the wide range of cognitive tests assessing different domains of cognition that are often incorporated in comprehensive cognitive assessments. Endpoints used in clinical practice and in AD clinical trials as well the meaning and measurement of clinical meaningfulness are also explored. Finally, the role of telemedicine in the management of AD is discussed including examples of validated assessments for remote administration.

This webinar explores the core cerebrospinal fluid (CSF) biomarkers (Aβ1–42, Aβ42/40, p-tau, and t-tau) in relation to the pathological changes associated with Alzheimer’s disease (AD). It describes how these core CSF biomarkers can support the early diagnosis of AD, and how emerging fluid biomarkers may be used as a complement to these core biomarkers for the diagnosis and prognosis of AD. This presentation also describes how to conduct a lumbar puncture with an emphasis on the importance of following standardized procedures for CSF sampling, storing, and testing. The clinical utility of CSF biomarker ratios, and considerations for biomarker disclosure are also addressed.

This webinar will review the various imaging modalities that can be used to support a diagnosis of Alzheimer’s disease (AD) including magnetic resonance imaging (MRI), computed tomography (CT) scanning, and amyloid and fluorodeoxyglucose positron emission tomography (FDG-PET), as well as tau PET, which is not yet approved in Canada but is currently being researched as a promising diagnostic marker. The presentation also addresses specifically the information provided by MRI and high-resolution CT in AD diagnosis, and describes the role of amyloid PET, FDG-PET, and single photon emission computed tomography regional cerebral blood flow (SPECT rCBF) in supporting a diagnosis of AD.

This webinar explores the core cerebrospinal fluid (CSF) biomarkers (Aβ1–42, Aβ42/40, p-tau, and t-tau) in relation to the pathological changes associated with Alzheimer’s disease (AD). It describes how these core CSF biomarkers can support the early diagnosis of AD, and how emerging fluid biomarkers may be used as a complement to these core biomarkers for the diagnosis and prognosis of AD. This presentation also describes how to conduct a lumbar puncture with an emphasis on the importance of following standardized procedures for CSF sampling, storing, and testing. The clinical utility of CSF biomarker ratios, and considerations for biomarker disclosure are also addressed.

This webinar will review the various imaging modalities that can be used to support a diagnosis of Alzheimer’s disease (AD) including magnetic resonance imaging (MRI), computed tomography (CT) scanning, and amyloid and fluorodeoxyglucose positron emission tomography (FDG-PET), as well as tau PET, which is not yet approved in Canada but is currently being researched as a promising diagnostic marker. The presentation also addresses specifically the information provided by MRI and high-resolution CT in AD diagnosis, and describes the role of amyloid PET, FDG-PET, and single photon emission computed tomography regional cerebral blood flow (SPECT rCBF) in supporting a diagnosis of AD.

This webinar provides an overview of the detection and management of amyloid-related imaging abnormalities due to vasogenic edema (ARIA-E) and amyloid-related imaging abnormalities due to micro-hemorrhages and macro-hemorrhages (ARIA-H). It explores the proposed mechanisms of disease and known risk factors of ARIA-E and ARIA-H, and examines the clinical relevance of ARIA-E and ARIA-H based on observations from clinical trials of anti-Aβ monoclonal antibodies. Supported by numerous imaging scans, the presentation describes how to identify ARIA-E and ARIA-H and how to distinguish them from other pathologies as well as how to manage ARIA in symptomatic versus asymptomatic patients with Alzheimer’s disease (AD).

This webinar provides an overview of the detection and management of amyloid-related imaging abnormalities due to vasogenic edema (ARIA-E) and amyloid-related imaging abnormalities due to micro-hemorrhages and macro-hemorrhages (ARIA-H). It explores the proposed mechanisms of disease and known risk factors of ARIA-E and ARIA-H, and examines the clinical relevance of ARIA-E and ARIA-H based on observations from clinical trials of anti-Aβ monoclonal antibodies. Supported by numerous imaging scans, the presentation describes how to identify ARIA-E and ARIA-H and how to distinguish them from other pathologies as well as how to manage ARIA in symptomatic versus asymptomatic patients with Alzheimer’s disease (AD).